Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors
Inhibitors of the proteolytic activity of the 20S proteasome have transformed the treatment of multiple B-cell malignancies. These agents have also been employed with success in the treatment of patients with autoimmune diseases and immune-mediated disorders. However, new agents are needed to fully...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI AG
2021-12-01
|
| Reeks: | Cells |
| Onderwerpen: | |
| Online toegang: | https://www.mdpi.com/2073-4409/11/1/9 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|